UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A
(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2021

AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)

Delaware	000-56036	83-3299164
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 Sutter Street Suite 1300 San Francisco, California	94104
(Address of principal executive offices)	(Zip Code)

(888) 669-4885
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: none.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

On April 13, 2021, Augmedix, Inc. (the "Company") filed a current report on Form 8-K (the "Original Report") furnishing on Exhibit 99.1 thereto the Company's unaudited quarterly financial results for 2020 and 2021. This Amendment No. 1 on Form 8-K/A (the "Amended Report") is being filed to correct an inadvertent error in Exhibit 99.1 regarding the net loss amount for the fourth quarter ended December 31, 2020. The Original Report reported a net loss of $3.971 million for the fourth quarter ended December 31, 2020, but the correct net loss amount for such quarter is $3.791 million. This Amended Report supersedes and replaces the Original Report in its entirety.

Item 2.02. Results of Operations and Financial Condition.

The Company is furnishing on Exhibit 99.1 attached hereto the Company's unaudited quarterly financial results for 2020 and 2019 for investors and analysts of the Company.

The information furnished with this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Exhibit.

(d) Exhibits

99.1	Augmedix, Inc.'s Unaudited Quarterly Financial Results for 2020 and 2019
104	Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AUGMEDIX, INC.

Date: April 14, 2021

By: /s/ Paul L Ginocchio
Paul L Ginocchio
Chief Financial Officer

Exhibit 99.1

Augmedix, Inc.
Summary Condensed Consolidated Statement of Operations
(in thousands except Average Clinicians in Service)

	Three Months Ended (unaudited)				Three Months Ended (unaudited)			
	3/31/2019	**6/30/2019**	**9/30/2019**	**12/31/2019**	**3/31/2020**	**6/30/2020**	**9/30/2020**	**12/31/2020**
Revenue	$ 3,185	$ 3,297	$ 3,668	$ 3,958	$ 3,970	$ 3,725	$ 4,245	$ 4,543
Cost of revenue	2,254	2,238	2,340	2,596	2,590	2,195	2,368	2,536
Gross profit	**931**	**1,059**	**1,328**	**1,362**	**1,380**	**1,530**	**1,877**	**2,007**
General and administrative	2,779	2,884	2,595	2,604	2,868	2,276	3,336	3,087
Sales and marketing	724	910	1,000	949	1,239	819	887	1,453
Research and development	1,555	1,676	1,951	1,795	1,491	985	1,009	1,037
Total operating expenses	5,058	5,470	5,546	5,348	5,598	4,080	5,232	5,577
Loss from operations	(4,127)	(4,411)	(4,218)	(3,986)	(4,218)	(2,550)	(3,355)	(3,570)
Other income (expense), net	96	237	(2,397)	308	(520)	(409)	(761)	(221)
Net loss	$ (4,031)	$ (4,174)	$ (6,615)	$ (3,678)	$ (4,738)	$ (2,959)	$ (4,116)	$ (3,791)
Reconciliation of Non-GAAP Metrics								
Net loss	$ (4,031)	$ (4,174)	$ (6,615)	$ (3,678)	$ (4,738)	$ (2,959)	$ (4,116)	$ (3,971)
Interest	460	440	1,479	433	356	439	402	256
Tax	14	30	28	39	48	25	26	9
Depreciation	228	227	234	260	218	215	213	221
EBITDA	(3,329)	(3,477)	(4,874)	(2,946)	(4,116)	(2,280)	(3,475)	(3,305)
Transaction Related Expenses	-	-	-	-	-	-	753	314
Adjusted EBITDA	$ (3,329)	$ (3,477)	$ (4,874)	$ (2,946)	$ (4,116)	$ (2,280)	$ (2,722)	$ (2,991)
GAAP Operating Expenses	$ 5,058	$ 5,470	$ 5,546	$ 5,348	$ 5,598	$ 4,080	$ 5,232	$ 5,577
Transaction Related Expenses	-	-	-	-	-	-	753	314
Adjusted Operating Expenses	$ 5,058	$ 5,470	$ 5,546	$ 5,348	$ 5,598	$ 4,080	$ 4,479	$ 5,263
Average Clinicians in Service	398	439	493	518	551	530	552	590

Included for each quarter is the **Average Clinicians in Service** Headcount. We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our services. We average the month end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the average number of clinicians in service is a key indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.

Augmedix, Inc.
Summary Condensed Consolidated Balance Sheet
(in thousands)

	As of:							
	3/31/2019	**6/30/2019**	**9/30/2019**	**12/31/2019**	**3/31/2020**	**6/30/2020**	**9/30/2020**	**12/31/2020**
	(unaudited)							
Assets								
Current assets:								
Cash	$ 5,635	$ 3,410	$ 15,822	$ 9,603	$ 4,223	$ 3,411	$ 1,429	$ 20,762
Restricted cash	-	-	-	2,000	2,000	2,000	2,000	2,211
Accounts receivable, net of allowance for doubtful accounts	2,163	2,523	1,974	2,291	2,656	2,992	2,562	2,693
Prepaid expenses and other current assets	423	459	497	459	492	555	412	1,104
Total current assets	8,221	6,392	18,293	14,353	9,371	8,958	6,403	26,770
Property and equipment, net	1,260	1,186	1,134	1,213	1,258	1,094	995	992
Deferred offering costs	-	-	-	-	-	-	935	-
Deposits	156	156	156	173	173	173	173	173
Total assets	$ 9,637	$ 7,734	$ 19,583	$ 15,739	$ 10,802	$ 10,225	$ 8,506	$ 27,935
Liabilities, Convertible Preferred Stock and Stockholders' equity (deficit)								
Current liabilities:								
Notes payable, current portion	$ 3,674	$ 3,224	$ 3,824	$ 2,894	$ 2,894	$ 2,894	$ 2,894	$ 2,894
Subordinated note payable, current portion	-	-	-	-	-	1,804	2,747	3,719
Accounts payable	483	755	707	641	565	590	291	259
Accrued expenses and other current liabilities	1,885	2,404	2,515	2,766	2,143	2,221	3,888	3,109
Deferred revenue	4,687	6,660	5,968	5,510	5,210	4,902	5,166	5,439
Customer deposits	1,189	1,084	1,053	1,053	1,053	1,053	1,053	1,053
Total current liabilities	11,918	14,127	14,067	12,864	11,865	13,464	16,039	16,473
Notes payable, net of current portion	-	-	-	-	-	2,180	2,180	2,180
Subordinated note payable, net of current portion	10,046	10,136	8,648	9,722	9,758	8,081	7,221	6,158
Deferred rent, net of current portion	231	114	114	21	21	-	-	-
Preferred stock warrant liability	175	154	4,942	4,391	4,657	4,673	5,253	-
Total liabilities	$ 22,370	$ 24,531	$ 27,771	$ 26,998	$ 26,301	$ 28,398	$ 30,693	$ 24,811

Commitments and contingencies								
Convertible preferred stock	38,257	38,257	53,430	53,882	54,283	54,283	54,283	-
Total stockholders' equity (deficit)	(50,990)	(55,054)	(61,618)	(65,141)	(69,782)	(72,456)	(76,470)	3,124
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 9,637	$ 7,734	$ 19,583	$ 15,739	$ 10,802	$ 10,225	$ 8,506	$ 27,935

Augmedix, Inc.
Condensed Consolidated Statement of Cash Flows

(in thousands)	Three Months Ended (unaudited)				Three Months Ended (unaudited)			
	3/31/2019	**6/30/2019**	**9/30/2019**	**12/31/2019**	**3/31/2020**	**6/30/2020**	**9/30/2020**	**12/31/2020**
Cash flows from operating activities:								
Net loss	$ (4,031)	$ (4,174)	$ (6,615)	$ (3,678)	$ (4,738)	$ (2,959)	$ (4,116)	$ (3,971)
Adjustments to reconcile net loss to net cash used in operating activities								
Depreciation and amortization	228	226	234	261	218	214	213	222
Stock-based compensation	86	107	101	103	97	295	99	177
Non-cash interest expense	74	89	1,161	98	36	128	83	(91)
Change in fair value of preferred stock warrant liability	(154)	(20)	920	(674)	170	16	580	(22)
Allowance for doubtful accounts	-	(1)	-	(2)	-	-	-	-
Deferred rent	(53)	(55)	(55)	(55)	172	(276)	(53)	(53)
Changes in operating assets and liabilities:			-	-			-	-
Accounts receivable	3	(290)	473	(312)	(365)	(248)	342	(131)
Prepaid expenses and other current assets	(4)	(37)	(37)	39	(28)	(70)	142	(691)
Deposits	(1)	-	-	(40)	-	-	-	-
Accounts payable	36	451	(46)	(67)	(32)	(99)	(230)	(36)
Accrued expenses and other current liabilities	(149)	205	136	338	(848)	373	929	44
Deferred revenue	(179)	1,973	(692)	(458)	(301)	(307)	264	272
Customer deposits	28	(105)	(32)	-	-	-	-	-
Net cash used in operating activities	**$ (4,116)**	**$ (1,631)**	**$ (4,452)**	**$ (4,447)**	**$ (5,619)**	**$ (2,933)**	**$ (1,747)**	**$ (4,100)**
Cash flows from investing activities:								
Purchase of property and equipment	(149)	(151)	(183)	(340)	(257)	(58)	(112)	(220)
Net cash used in investing activities	**$ (149)**	**$ (151)**	**$ (183)**	**$ (340)**	**$ (257)**	**$ (58)**	**$ (112)**	**$ (220)**
Cash flows from financing activities:								
Cash paid in connection with the Merger, net of cash acquired	-	-	-	-	-	-	-	(46)
Payment to unaccredited investors of Augmedix Operating Corporation	-	-	-	-	-	-	-	(555)
Proceeds from notes payable	-	-	-	-	-	2,180	-	-
Repayment of notes payable	-	(450)	(908)	-	-	-	-	-
Proceeds from sale of common stock	-	-		-	-	-	-	27,416
Proceeds from issuance of convertible preferred stock	-	-	14,696	575	500	-	-	-
Proceeds from issuance of convertible notes payable	-	-	3,304	-	-	-	-	-
Payment of financing costs	-	-	(45)	(8)	(4)	-	(125)	(3,030)
Proceeds from exercise of stock options	-	1	3	-	2	-	-	78
Net cash provided by (used in) financing activities	**$ -**	**$ (449)**	**$ 17,050**	**$ 567**	**$ 498**	**$ 2,180**	**$ (125)**	**$ 23,863**
Effect of exchange rate changes on cash and restricted cash	(14)	6	(3)	1	(2)	(1)	2	1
Net decrease in cash and restricted cash	(4,279)	(2,225)	12,412	(4,219)	(5,380)	(812)	(1,982)	19,544
Cash and restricted cash at beginning of period	9,914	5,635	3,410	15,822	11,603	6,223	5,411	3,429
Cash and restricted cash at end of period	$ 5,635	$ 3,410	$ 15,822	$ 11,603	$ 6,223	$ 5,411	$ 3,429	$ 22,973